+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and effects of marstacimab, a study medicine, for treating hemophilia in male pediatric patients aged 1 to 17 years. The study focuses on severe Hemophilia A and moderately severe to severe Hemophilia B, including participants with or without inhibitors. Enrollment is done sequentially by age groups starting with adolescents, then children aged 6 to 11 years, followed by children aged 1 to 5 years. All participants will receive weekly subcutaneous injections of marstacimab, initially administered at the study site with subsequent doses given either at home or at the study site over a 12-month treatment period. The study compares participants experiences during treatment to their historical bleeding and treatment records to assess how marstacimab may help prevent bleeding episodes common in hemophilia. Participants will be involved for about 14 months, including a screening period of roughly one month, 12 months of treatment, and a one-month follow-up. They will attend at least 10 study visits, with the option of completing two visits at home if regulations allow, and receive six scheduled phone calls approximately every two months. Researchers will monitor bleeding rates, safety events, immune responses, joint health, and quality of life during this time.

Age: 1Year - 17YearsMALEPhase 3
63 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.

Age: 18Years +All GendersPhase 2
129 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared with placebo to reduce the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT in pregnant women who have had previous pregnancies affected by this condition. This phase 3 study focuses on at-risk pregnancies where the fetus is confirmed to have a specific platelet antigen, and the mother has antibodies against it. The goal is to assess whether nipocalimab can lower the risk of severe bleeding, low platelet counts, or death in the fetus or newborn. Participants will be randomly assigned to receive either nipocalimab or a placebo intravenously during pregnancy, between weeks 13 and 18 of gestation. The study is double-blind, so neither participants nor researchers know which treatment is given. Maternal health and fetal status will be closely monitored throughout pregnancy and up to 24 weeks postpartum. The study also tracks adverse events, antibody responses, and infant development up to 104 weeks after birth. Participants will undergo assessments including physical exams, medical history reviews, vital signs, ECGs, and laboratory tests at screening and during the study. Researchers will measure outcomes such as the occurrence of severe bleeding, platelet counts at birth, need for platelet transfusions, and infant development using the Bayley Scales at 52 and 104 weeks. Safety is monitored for both mothers and infants throughout the study period, which lasts until approximately two years after birth.

Age: 18Years - 45YearsFEMALEPhase 3
21 locations
C

Actively Recruiting

Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.

Age: 18Years +All GendersPhase 3
89 locations
E

Actively Recruiting

Researchers are studying targeted therapies for adults with moderately to severely active Rheumatoid Arthritis RA, a chronic condition causing joint pain, stiffness, swelling, and loss of function. This Phase 2 trial aims to evaluate the safety and effectiveness of three different treatment approaches compared to placebo in participants who have not responded well to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs btsDMARDs. The study includes three substudies Lutikizumab monotherapy versus placebo, Ravagalimab monotherapy versus placebo, and a combination of Lutikizumab and Ravagalimab versus placebo. Treatments are given as subcutaneous injections with participants randomized to receive either active drugs or matching placebo doses. Approximately 180 participants will enroll and receive study treatments during the trial. Participants will have regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. The main outcomes measured include the percentage of participants achieving significant improvement in RA symptoms American College of Rheumatology 50% response at 12 weeks and tracking adverse events up to about 22 weeks. The study continues until November 2027 with ongoing safety and efficacy monitoring.

Age: 18Years +All GendersPhase 2
96 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of three drugsfrexalimab, brivekimig, and rilzabrutinibin people aged 16 to 75 years who have primary focal segmental glomerulosclerosis FSGS or minimal change disease MCD. This Phase 2a, double-blind, placebo-controlled study aims to measure changes in proteinuria and how these drugs impact remission rates in nephrotic syndrome. Participants will be randomly assigned to one of six groups, receiving either frexalimab, brivekimig, rilzabrutinib, or a matching placebo. Treatment lasts 24 weeks, with the overall study duration up to 52 weeks. Participants will attend up to 16 visits during the study to receive the treatments and undergo assessments. Throughout the trial, participants will have their urine protein to creatinine ratio UPCR measured to assess treatment impact, particularly focusing on changes from baseline to Week 12. Other evaluations include tracking remission rates, monitoring for adverse events, and measuring drug concentrations and antibody responses up to Week 48. Participants will be closely monitored for safety and treatment effects during the study period.

Age: 16Years - 75YearsAll GendersPhase 2
79 locations

1-10 of 27

1